Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 10Recruiting 4Unknown 3Terminated 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2Interventional 2

Sponsor

Conditions

Tuberous Sclerosis 1Liver Cirrhosis 1Lennox Gastaut Syndrome 1Epilepsies, Myoclonic 1Anxiety Disorders 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Cannabidiol × Clear all
NCT05044819 2026-06-01

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Jazz Pharmaceuticals

Phase 4 Active not recruiting
154 enrolled

Epilepsies, Myoclonic, Liver Cirrhosis, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT04482244 2025-07-29

RCT of CBD for Anxiety in Advanced Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 11 charts

Anxiety Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡